Steven Tian

Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Steven Tian argue that Cook’s unmatched track record makes him uniquely positioned to steer the company into its next phase of innovation and growth.

Meta has lured a string of top researchers from rivals with nine-figure pay packages in an effort to close the gap with AI leaders like OpenAI, Anthropic, and Google. But splashy hires rarely end up rescuing flailing enterprises, write Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Steven Tian.

President Donald Trump is an AI booster, write Yale SOM’s Jeffrey Sonnenfeld and co-authors Stephen Henriques and Steven Tian. So they thought it was fair to ask the leading chatbots to evaluate some of Trump’s frequently repeated claims.

Yale’s Jeffrey Sonnenfeld and co-authors suggest that some of New York City mayoral candidate Zohram Mamdani’s socialism-inspired proposals, such as city-owned grocery stores, are likely to run into inefficiencies and unanticipated downsides. They write that capitalism can be a better engine of progress.

Elon Musk has less leverage in his battle with Donald Trump than he thinks, Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Steven Tian write. But neither of the former allies can come away from this feud with a win.

Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian write that the administration’s unpredictable approach is bringing new corporate initiatives to a standstill and pushing the economy toward recession.

Amid warming relations with Washington, Vladimir Putin is floating new opportunities for Western companies in Russia. But Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian write that business leaders are reluctant to reengage in a dangerous setting and a faltering economy.

Yale SOM’s Jeffrey Sonnenfeld and co-authors Stephen Henriques and Steven Tian write that while there are legitimate reasons for some tariffs, the president’s arbitrary approach is worrying allies and unsettling markets.

Leadership expert Jeffrey Sonnenfeld and co-author Steven Tian look across history for examples of pitfalls that could lie ahead for Elon Musk and Donald Trump.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.